TY - JOUR ID - 164012 TI - Role of Biomaterials in treatment of Alzheimer’s disease: A literature review JO - Neurology Letters JA - NL LA - en SN - AU - Ramezannezhad, Elham AD - School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran Y1 - 2022 PY - 2022 VL - 1 IS - 2 SP - 64 EP - 68 KW - Keywords: Alzheimer's disease KW - Biomaterials KW - Nanocarriers KW - Nanoparticles DO - 10.52547/nl.1.2.64 N2 - Currently, five medications have been approved by the FDA to treat Alzheimer's disease (AD); Donepezil, which is used at all stages of AD, galantamine, and rivastigmine for mild to moderate stages, and Memantine and a combination of Memantine and donepezil for moderate to severe stages. The ability of these drugs to cross the blood-brain barrier (BBB) determines their exact efficacy. Numerous biomaterials were introduced as a vector for drug agents and increased bioavailability. In this review, we summarized several biomaterials which were used in the treatment of AD. UR - https://www.neurologyletters.com/article_164012.html L1 - https://www.neurologyletters.com/article_164012_c8a958a71f54b569e1ef0b18f51f5309.pdf ER -